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Pyocardial Delayed Enhancement by Magnetic
esonance Imaging in Patients With Chagas’ Disease
Marker of Disease Severity
arlos E. Rochitte, MD,* Paulo F. Oliveira, MD,* Joalbo M. Andrade, MD,* Bárbara M. Ianni, MD,*
osé R. Parga, MD,* Luiz F. Ávila, MD,* Roberto Kalil-Filho, MD, FACC,* Charles Mady, MD,*
osé C. Meneghetti, MD,* João A. C. Lima, MD, FACC,† José A. F. Ramires, MD, FACC*
ão Paulo, Brazil; and Baltimore, Maryland
OBJECTIVES We sought to investigate whether myocardial delayed enhancement (MDE) by magnetic
resonance imaging (MRI) could quantify myocardial fibrosis (MF) in patients with Chagas’
heart disease (CHD), thus defining the severity of the disease.
BACKGROUND Myocardial fibrosis secondary to ischemic disease can be imaged using MDE. Advanced
CHD is characterized by progressive MF.
METHODS Fifty-one patients with CHD were enrolled: 15 seropositive asymptomatic participants in the
indeterminate phase (IND); 26 patients with known clinical CHD; and 10 patients with
known CHD and ventricular tachycardia (VT). Using a 1.5-T MRI system, we acquired left
ventricular (LV) short-axis slices using cine-MRI (LV function) and inversion-recovery
gradient-echo (MDE).
RESULTS Myocardial fibrosis by MRI was present in 68.6% of all patients, in 20% of IND, 84.6% of
CHD, and 100% of VT (p  0.001). Quantified MF increased progressively across disease
severity subgroups (0.9  2.3% in IND; 16.0  12.3% in CHD; and 25.4  9.8% in VT, p
 0.001) and New York Heart Association functional classes (I: 7.5  9.5%; II: 21.9 
13.8%; and III: 25.3  9.9% of LV mass, p  0.001). Left ventricular ejection fraction and
MF had significant negative correlation (r0.78, p 0.001), similar to the segmental MF
and function: 4.9  15.1% of MF in normal function, 32.5  32.5% in mildly hypokinetic,
57.8 31.4% in severely hypokinetic, and 72.3 36.2% in akinetic and dyskinetic segments,
respectively (p  0.001).
CONCLUSIONS In CHD, MDE by MRI quantifies MF that not only can be detected in the early
asymptomatic stages but parallels well-established prognostic factors and provides unique
information for clinical disease staging. (J Am Coll Cardiol 2005;46:1553–8) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.067the American College of Cardiology Foundation
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ahagas’ disease is a chronic disease that is caused by
rypanosoma cruzi infection (1), a pathogen that has been
fflicting humans for millennia (2). The disease currently
ffects 4% to 7% of Latin Americans, with 200,000 new
ases annually (3). Chagas’ heart disease (CHD) is the most
erious complication, striking approximately one-third of
eropositive individuals and is a main cause of death from
eart failure in Latin America.
After infection with T. cruzi (4), the asymptomatic phase
an last for decades (indeterminate) until unknown triggers
nitiate disease progression to heart failure and arrhythmias
n a subset of patients. Pathologic studies of advanced CHD
ave shown prominent myocardial fibrosis (MF) (5–7).
owever, serial in vivo quantification of MF across different
tages of Chagas’ disease has not been previously performed.
Myocardial delayed enhancement (MDE) by magnetic
esonance imaging (MRI) is the best noninvasive method to
valuate MF or necrosis caused by acute, chronic myocardial
nfarction (8–11) or non-ischemic myocardial disease (12).
From the *Heart Institute (InCor), University of São Paulo Medical School, São
aulo, Brazil, and the †Cardiolgy Division, Department of Medicine, Johns Hopkins
niversity, Baltimore, Maryland. Supported by FAPESP (Fundação de Amparo ã
esquisa do Estado de São Paulo) Grant 01/04358–0 and the Zerbini Foundation.i
Manuscript received January 5, 2005; revised manuscript received May 23, 2005,
ccepted June 20, 2005.e hypothesized that MDE quantifies myocardial damage
aused by CHD at different stages of disease severity. Our
bjectives were to evaluate the extent, location, and fre-
uency of MF in Chagas’ disease and to determine its
elation to established parameters of disease severity.
ETHODS
e evaluated 51 seropositive patients for Chagas’ disease
ithout history of myocardial infarction and at low risk for
oronary artery disease (CAD). All patients signed an
nCor-approved consent form. Exclusion criteria were pre-
ious infarction or CAD, 2 CAD risk factors, valve
isease, and MRI contraindications. We enrolled three
ubgroups at distinct stages of disease progression (Table 1)
ased on well-recognized markers of worse prognosis (New
ork Heart Association [NYHA] functional classification,
eft ventricular [LV] ejection fraction [LVEF], LV volumes,
lectrocardiogram abnormalities, and ventricular tachycar-
ia) (4,13–15). They consisted of: 1) an indeterminate
roup (IND group) of 15 asymptomatic patients without
igns of cardiac involvement by CHD with normal echo-
ardiography, MRI, electrocardiogram, and chest X-ray; 2)
CHD group of 26 consecutive patients with known heartnvolvement by CHD defined as abnormal electrocardio-
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emiblock) and/or LV dysfunction; and 3) a ventricular
achycardia (VT) group comprising 10 patients with known
HD, with previously documented episode of ventricular
achycardia, and with normal coronary angiography. All
atients in the VT group underwent coronary angiography
nd electrophysiologic studies within one year from the
RI study.
agnetic resonance imaging methods. All patients had
RI examination on 1.5-T GE CV/i System (Wakeusha,
able 1. Patient Characteristics
All (n  51) IND (n
ale gender 19 (37.3) 2 (1
ge (yrs) 50.4  12.9 46.5 
VEF (%) 49.0  17.8 65.7 
SV (ml/m2) 43.9  33.8 20.3 
DV (ml/m2) 77.4  35.8 58.3 
V mass (g/m2) 64.6  23.5 57.5 
ean NYHA functional class 1.5  0.6 1.0 
YHA functional class I 20 (39.2) 0
MI (kg/m2) 24.1  4.0 24.2 
ypertension 1 (2.0) 0
iabetes 1 (2.0) 0
ypercholesterolemia 7 (13.8) 2 (1
urrent smoker 1 (2.0) 1 (6
AD family history 1 (2.0) 0
ata are expressed as mean  SD or number (%) for discrete variables. *Fisher’s
anks-Kruskal-Wallis test.
BMI  body mass index; CHD  Chagas’ heart disease; EDV  end-diastolic v
left ventricular ejection fraction; NYHA  New York Heart Association; VT 
Abbreviations and Acronyms
CAD  coronary artery disease
CHD  Chagas’ heart disease
IND  indeterminate phase group
LV  left ventricular
LVEF  left ventricular ejection fraction
MDE  myocardial delayed enhancement
MF  myocardial fibrosis
MRI  magnetic resonance imaging
NYHA  New York Heart Association
VT  ventricular tachycardiaigure 1. Myocardial delayed enhancement (arrowheads) on left ventricular sho
isease group; IND  indeterminate phase group; VT  Chagas’ heart diseaseisconsin). Left ventricular short-axis and long-axis imag-
ng planes were obtained, during an 8- to 15-s breath-hold,
y two electrocardiogram-triggered pulse sequences at the
ame exact locations, allowing precise comparisons between
V function and myocardial structure.
A gradient-echo (steady-state free precession) was used
or LV function evaluation, and an inversion-recovery pre-
ared gradient-echo was used for MDE (10 to 20 min after
ntravenous bolus of 0.2 mmol/kg of gadolinium-based
ontrast), with the following parameters, respectively: rep-
tition time 3.9/7.1 ms, echo time 1.7/3.1 ms, flip angle
5°/20°, cardiac phases 20/1, views per segment 8/16 to 32,
atrix 256  128/256 192, slice thickness 8/8 mm, gap
etween slices 2/2 mm and field of view 32 to 38/32 to 38
m, inversion time none/150 to 250 ms, receiver bandwidth
25/31.25 kHz, number of excitations 1/2, acquisition every
eart beat for both.
ata analysis. End-systolic, end-diastolic LV volumes,
nd LVEF were measured by MASS-plus Analysis software
Leiden, the Netherlands), applying Simpson’s method. On
he MDE short-axis images, LV mass and total extent of
DE (as percent of LV mass) were measured using
) CHD (n  26) VT (n  10) p Value
12 (46.2) 5 (50.0) 0.068*
49.3  12.7 58.9  12.0 0.049†
45.7  16.0 32.3  12.7 0.001†
48.3  36.1 68.0  32.0 0.001‡
80.7  41.0 97.7  32.2 0.005‡
61.2  25.5 83.9  18.2 0.005‡
1.5  0.6 2.2  0.6 0.001‡
11 (42.3) 9 (90) 0.001*
24.5  4.7 22.8  2.8 0.523‡
1 (3.9) 0 1.000*
0 1 (10) 0.196*
3 (11.54) 2 (20.0) 0.864*
0 0 0.490*
0 1 (10) 0.196*
test. †One-way analysis of variance (ANOVA). ‡One-way analysis of variance by
; ESV  end-systolic volume; IND  indeterminate; LV  left ventricular; LVEF
ular tachycardia. 15
3.3)
12.0
7.5
7.0
14.3
16.0
0.0
3.4
3.3)
.7)
exactrt-axis slices in different stages of Chagas’ disease. CHD  Chagas’ heart
with ventricular tachycardia group.
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ejection fraction (65.5%). (B) Patient with large area of MF (23.8%) and severe l
 myocardial delayed enhancement; MRI  magnetic resonance imaging.
T
W
W
M
D
 p  0.001, IND vs. VT  p  0.001 and CHD vs. VT  p  0.044. Adjusted p valu
MF  myocardial fibrosis by magnetic resonance imaging [MRI]; other abbreviations a
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ethesda, Maryland). Segmental MDE transmurality and
yocardial function were scored (by two observers) using
tandard LV 17-segment model (16), as the visual percent
rea enhanced (25%, 26% to 50%, 51% to 75%, and
75%) and as normal, mild hypokinesia, severe hypokine-
ia, and akinesia or dyskinesia. Additionally, pattern of
DE was classified as subendocardial, midwall, subepicar-
ial, or transmural.
tatistical analysis. Comparisons of normally distributed
ontinuous variables were performed by the Student t test
nd one-way analysis of variance with Bonferroni test for
ultiple comparisons. The Fisher exact test was used for
roportions comparisons. The nonparametric test for dis-
rete variables and non-normal continuous variables was
ruskal-Wallis rank test. Normality was determined by
hapiro-Francia W’ test. Simple linear regression was used
etween the MF mass and LVEF, end-diastolic volume,
nd end-systolic volume. For the segmental analysis, we
ion. (A) Patient with small area of MF (8.2%) and normal left ventricular
CHD (n  26) VT (n  10) p Value
22 (84.6) 10 (100)
4 (15.4) 0 (0)  0.001*
16.0  12.3 25.4  9.8  0.001†
; †one-way ANOVA with Bonferroni multiple (3) comparison test; IND vs. CHD
e for significance is p  0.05/3 or p  0.016.
s in Table 1.igure 2. Increase in myocardial fibrosis (MF) over New York Heart
ssociation functional classes (p  0.001 by analysis of variance). Class I
ad less MF than classes II and III (multiple [3] comparisons by
onferroni test, with adjusted p value for significance p  0.016: I vs. II p
0.001; II vs. III p  1.0; I vs. III p  0.012). LV  left ventricular.igure 3. Extent of myocardial fibrosis (MF) (arrows) and left ventricular functable 2. Myocardial Fibrosis by MRI
All (n  51) IND (n  15)
ith MF 35 (68.6) 3 (20.0)
ithout MF 16 (31.4) 12 (80.0)
F (% of LV mass) 13.4  13.2 0.9  2.3
ata are expressed as mean  SD or number (%) for discrete variables. *Fisher’s exact testeft ventricular dysfunction (left ventricular ejection fraction 19.2%). MDE
u
j
i
r
p
l
c
R
M
(
h
a
i
C
s
(
w
t
G
s
a
[
o
c
s
4
c
0
S
8
u
m
d
w
o
3
g
g
g
o
s
m
n
o
a
s
e
R
F
1
b
(
t
F
(
q
F
d
p
1556 Rochitte et al. JACC Vol. 46, No. 8, 2005
Myocardial Fibrosis in Chagas’ Disease October 18, 2005:1553–8sed ordered logistic regression with standard errors ad-
usted for clustering on patients to consider the non-
ndependence of the segmental measurements. Interstudy
eproducibility was measured by mean differences and re-
eatability coefficient (2 SD). Stata 8.0 (Stata Corp., Col-
ege Station, Texas) was used, and p  0.05 (two-tailed)
onsidered statistically significant.
ESULTS
yocardial fibrosis was detected in 35 of 51 patients
68.6%), in all groups (Fig. 1), and with a progressively
igher proportion of patients with MF from IND to CHD
nd VT groups (Table 2). Similarly, the magnitude of MF
ncreased progressively (Table 2).
linical status. Quantitative MF also increased progres-
ively from NYHA functional class I to II and III patients
Fig. 2). Among patients without MF, only 12.5% (2 of 16)
ere in NYHA classI compared with 51.4% (18 of 35) of
hose with MF (p  0.012, by the Fisher exact test).
igure 4. Good correlation between left ventricular ejection fraction
LVEF) and myocardial fibrosis (MF). Patients with LVEF40% had less
uantified MF than those with LVEF 40% (Student t test).
igure 5. Left ventricular 17-segment model showing concentration on a
elayed enhancement (MDE) (A) (51.3%, p 0.001 by the Fisher exact test and
 0.001 by the Fisher exact test and by logistic regression). Absolute numbelobal LV function. Patients with small areas of MF
howed preserved LV function, whereas patients with large
reas of MF had severe LV dysfunction (Fig. 3, Video 1
accompanying videos can be viewed with the online version
f this article]). Patients with LVEF 40% had signifi-
antly less MF than those with LVEF 40%, with a
ignificant inverse correlation between MF and LVEF (Fig.
). End-diastolic and end-systolic volumes indices also
orrelated directly with MF (r  0.57 and r  0.65, p 
.001).
egmental LV function and MF. Segmental MF (269 of
67) and dysfunction (290 of 867) were unequally distrib-
ted (apex, inferior, inferolateral segments significantly
ore involved; Fig. 5). Importantly, there was no segmental
ysfunction in IND group, even in segments with MF,
hich tended to be of limited degree.
Although atypical MDE patterns were observed in 46.9%
f LV segments (126 of 269: subepicardial, 12.3%; midwall,
4.6%), 53.1% were subendocardial or transmural, indistin-
uishable from infarction caused by CAD. Small, hetero-
eneous and diffuse MF patterns also were observed.
The more severe the degree of segmental dysfunction, the
reater the percent area of LV segmental enhancement
bserved (Fig. 6). Myocardial fibrosis increased progres-
ively from segments with normal function to those with
ild hypokinesia, severe hypokinesia, akinesia, and dyski-
esia (p 0.0001 by Kruskal-Wallis test). Reanalysis, using
rdered logistic regression with clustering on patients to
djust for the non-independence of the data, also showed
tatistical differences for all groups (p 0.001) and between
ach group (p  0.03 for all comparisons).
eproducibility and coronary angiography (VT group).
ive patients with MDE had a second MRI examination
.5 to 6 months later. Myocardial fibrosis mean difference
etween the second and first examination was 1.4  1.7%
18.5  11.2% vs. 17.0  10.5%, respectively, p  NS by t
est). The repeatability coefficient was 3.4%, and MDE
inferolateral, and inferior segments (shaded area) of regional myocardialpex,
p 0.002 by logistic regression) and wall motion abnormality (B) (51.7%,
r of segments and (percent values) are shown.
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October 18, 2005:1553–8 Myocardial Fibrosis in Chagas’ Diseaseegment distribution, size, and shape of areas were identical
n both examinations. All patients in the VT group had
xtensive MF (25.4  9.8%) but no obstructive CAD by
ngiography (Fig. 7, Video 2 [accompanying videos can be
iewed with the online version of this article]).
ISCUSSION
his study is the first to quantify myocardial fibrosis in vivo
y delayed enhanced MRI in patients with CHD. We
emonstrate that the degree of MF increases progressively
rom the mildest to the most severe disease stages. Addi-
igure 6. Segmental left ventricular function and extent of myocardial
brosis (MF). A progressive and significant increase of MF along with the
oss of segmental contractile activity can be observed.
igure 7. A ventricular tachycardia group patient with typical apical and inf
iddle, and left columns) and normal coronary arteries by angiographyvorticilar) observed on the ventriculogram (arrow, top right column) and cine
nding of Chagas’ heart disease. MDE  myocardial delayed enhancement; Rionally, MF correlates inversely with LVEF and clinical
tatus, which agrees with previous biopsy study, relating
nterstitial collagen deposition to LV dysfunction (5). The
ood correlation between the degree of MF by MDE and
stablished prognostic factors in CHD supports the role of
RI-defined fibrosis as a marker of disease severity. More-
ver, MRI provides evidence of myocardial involvement
mong seropositive patients without clinical symptoms or
all motion abnormality, which further supports the use of
RI-defined MF as a subclinical marker of disease severity.
The segmental MDE analysis indicates the LV apex and
nferolateral regions as preferable sites for MF, in accor-
ance with previous pathological studies (5–7,17). This
istribution supports the concept that MF develops in
egions of distal circulation due to T. cruzi-mediated mi-
rovascular disease, causing impaired perfusion to watershed
yocardial territories (6,17).
Persistent MDE from repeated MRI studies accompa-
ied by chronic elevation of biomarkers (18,19), myocardial
erfusion abnormalities by scintigraphy, and normal coro-
ary arteries by angiography (20) reflect the effect of
ontinued myocyte loss with relentless replacement by MF
s defined by previous pathological studies (6,17).
On the basis of the clinical profile of our study population
relatively young, low risk for CAD, no previous infarction
r CAD), the high incidence of MF (84.6% [22 of 26],
eral myocardial fibrosis by magnetic resonance imaging (arrows in bottom,
, middle, and left columns). The left ventricular (LV) apical aneurysmerolat
(top-magnetic resonance imaging (arrow, bottom right column) is a classical
CA  right coronary artery/
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Myocardial Fibrosis in Chagas’ Disease October 18, 2005:1553–8HD group), and the atypical pattern of MF when com-
ared with CAD (predominantly midwall and subepicardial
nd encompassing multiple coronary territories) we feel
onfident that the MDE regions documented in this study
re caused by CHD and not by CAD. To further exclude
AD, all patients in the group with documented VT
howed no obstructive CAD by angiography despite the
resence of large areas of MF (25.4  9.8%).
onclusions. Magnetic resonance imaging tissue charac-
erization by MDE enables the quantification of MF, which
dds important information on disease severity to the
ssessment of patients with CHD. These results also pro-
ide novel pathophysiologic insights into our current under-
tanding of CHD, particularly into indeterminate phase and
rrhythmias, which hopefully could be used to guide the
uture development of new therapeutic interventions de-
igned to halt myocardial fibrosis early in the subclinical
hases of the disease process.
eprint requests and correspondence: Dr. Carlos E. Rochitte,
irector of Cardiovascular MRI and CT, Instituto do Coração
InCor), Setor de Ressonaˆncia Magnética Cardiovascular, Av. Dr.
néas de Carvalho Aguiar, 44, Andar AB, Cerqueira César, São
aulo, SP, Brazil, 05403–000. E-mail: rochitte@incor.usp.br.
EFERENCES
1. Chagas C. Nova tripanosomiase humana. Mem Inst Oswaldo Cruz
1909;1:159–218.
2. Aufderheide AC, Salo W, Madden M, et al. A 9,000-year record of
Chagas’ disease. Proc Natl Acad Sci U S A 2004;101:2034–9.
3. World Health Organization. The World Health Report 2002. An-
nexes and Tables. Geneva: World Health Organization, 2002:192.
4. Marin Neto JA, Simoes MV, Sarabanda AV. Chagas’ heart disease.
Arq Bras Cardiol 1999;72:247–80.
5. Mady C, Ianni BM, Arteaga E, et al. Relation between interstitial
myocardial collagen and the degree of clinical impairment in Chagas’
disease. Am J Cardiol 1999;84:354–6.
6. Higuchi ML, Fukasawa S, De Brito T, Parzianello LC, Bellotti G,
Ramires JA. Different microcirculatory and interstitial matrix patterns7. Rossi MA. Patterns of myocardial fibrosis in idiopathic cardiomyop-
athies and chronic Chagasic cardiopathy. Can J Cardiol 1991;7:287–
94.
8. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed
contrast enhancement to irreversible injury, infarct age, and contractile
function. Circulation 1999;100:1992–2002.
9. Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time
course of microvascular obstruction and tissue injury after acute
myocardial infarction. Circulation 1998;98:1006–14.
0. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced
magnetic resonance imaging to identify reversible myocardial dysfunc-
tion. N Engl J Med 2000;343:1445–53.
1. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI
and routine single photon emission computed tomography (SPECT)
perfusion imaging for detection of subendocardial myocardial infarcts:
an imaging study. Lancet 2003;361:374–9.
2. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart
failure related to dilated cardiomyopathy and coronary artery disease
using gadolinium-enhanced cardiovascular magnetic resonance. Cir-
culation 2003;108:54–9.
3. Maguire JH, Hoff R, Sherlock I, et al. Cardiac morbidity and mortality
due to Chagas’ disease: prospective electrocardiographic study of a
Brazilian community. Circulation 1987;75:1140–5.
4. de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo
EE. Ventricular tachycardia during exercise testing as a predictor of
sudden death in patients with chronic chagasic cardiomyopathy and
ventricular arrhythmias. Br Heart J 1995;74:293–5.
5. Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F.
Survival and predictors of survival in patients with congestive heart
failure due to Chagas’ cardiomyopathy. Circulation 1994;90:3098–
102.
6. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized
myocardial segmentation and nomenclature for tomographic imaging
of the heart: a statement for healthcare professionals from the Cardiac
Imaging Committee of the Council on Clinical Cardiology of the
American Heart Association. Circulation 2002;105:539–42.
7. Higuchi Mde L, Benvenuti LA, Martins Reis M, Metzger M.
Pathophysiology of the heart in Chagas’ disease: current status and
new developments. Cardiovasc Res 2003;60:96–107.
8. Aras R, Bastos C, Mota G, et al. Troponin in chagas disease. Braz
J Infect Dis 2003;7:358–9.
9. Basquiera AL, Capra R, Omelianiuk M, Amuchastegui M, Madoery
RJ, Salomone OA. Serum troponin T in patients with chronic Chagas
disease. Rev Esp Cardiol 2003;56:742–4.
0. Marin-Neto JA, Marzullo P, Marcassa C, et al. Myocardial perfusion
abnormalities in chronic Chagas’ disease as detected by thallium-201
scintigraphy. Am J Cardiol 1992;69:780–4.
PPENDIX
or accompanying videos, please see the online version ofin idiopathic dilated cardiomyopathy and Chagas’ disease: a three
dimensional confocal microscopy study. Heart 1999;82:279–85. this article.
